Meadow Creek Wealth Advisors’s AstraZeneca AZN Stock Holding History

Meadow Creek Wealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$472K	Buy	2,491 +75	+3%	+$14.1K	0.29%	67
2026 Q1	$476K	Buy	2,416 +140	+6%	+$27K	0.31%	67
2025 Q4	$418K	Buy	2,276 +637	+39%	+$112K	0.27%	74
2025 Q3	$275K	Buy	1,639 +23	+1%	+$3.48K	0.18%	112
2025 Q2	$226K	Sell	1,616 -80	-5%	-$11.2K	0.15%	129
2025 Q1	$249K	Buy	1,696 +5	+0.3%	+$723	0.19%	115
2024 Q4	$222K	Buy	1,691 +20	+1%	+$2.8K	0.16%	125
2024 Q3	$260K	Sell	1,671 -1	-0.1%	-$161	0.21%	109
2024 Q2	$261K	Buy	1,672 +19	+1%	+$2.86K	0.25%	97
2024 Q1	$224K	Buy	1,653 +95	+6%	+$12.6K	0.16%	124
2023 Q4	$210K	Buy	+1,558	New	+$203K	0.2%	98
2019 Q4	$252K	Buy	+2,523	New	+$238K	0.35%	81

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Meadow Creek Wealth Advisors's AZN Position: Q2 2026 in Review

Meadow Creek Wealth Advisors increased its AstraZeneca (AZN) stake by 3.1% in Q2 2026, buying an estimated $14.1K and bringing the position to 2,491 shares worth $472K. The position accounts for 0.29% of the portfolio, ranked #67.

Meadow Creek Wealth Advisors first reported a position in AZN in Q4 2019 and has held it in 12 quarters since. The position peaked at $476K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Meadow Creek Wealth Advisors held 2,491 shares of AstraZeneca worth $472K as of Q2 2026.
Meadow Creek Wealth Advisors bought 75 AstraZeneca shares in Q2 2026, an estimated $14.1K.
AstraZeneca made up 0.29% of Meadow Creek Wealth Advisors's portfolio in Q2 2026, its #67 holding.
Meadow Creek Wealth Advisors first reported a position in AstraZeneca in Q4 2019 and has held it in 12 quarters since.
Meadow Creek Wealth Advisors's AstraZeneca position peaked at $476K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Meadow Creek Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.